Study guide

3.2 Systemic Clinical Physiology & Homeostasis

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

3.2 Systemic Clinical Physiology & Homeostasis

Key Takeaways Explain This Topic AI

Subendocardial perfusion of the left ventricle occurs predominantly during diastole; coronary perfusion pressure (CPP = Aortic Diastolic Pressure - LVEDP) is compromised by tachycardia, aortic regurgitation, and elevated ventricular filling pressures.

In acute respiratory failure, a normal A-a oxygen gradient in the presence of hypoxaemia confirms alveolar hypoventilation (e.g., central CNS depression or neuromuscular weakness) or low inspired FiO2, whereas V/Q mismatch or shunt widens the gradient.

Oxygen therapy in acute hypercapnic COPD exacerbations precipitates worsening acidosis primarily by reversing hypoxic pulmonary vasoconstriction (worsening V/Q mismatch and dead space ventilation) and via the Haldane effect, rather than blunt suppression of hypoxic respiratory drive alone.

Glomerular filtration rate is preserved during renal hypoperfusion through angiotensin II-mediated efferent arteriolar vasoconstriction and prostaglandin-mediated afferent arteriolar vasodilatation; concurrent ACE inhibitor and NSAID administration abruptly disrupts this compensatory autoregulation.

Vasopressin (ADH) binds basolateral V2 receptors in collecting duct principal cells, activating cAMP-protein kinase A signalling to induce apical membrane translocation of aquaporin-2 water channels.

Last updated: September 2026

Systemic clinical physiology in MRCP(UK) Part 1 tests haemodynamic principles, respiratory gas calculations, and neurohumoral fluid balance.

  • 1. Cardiovascular Mechanics & Reflexes
  • The Cardiac Cycle & Pressure-Volume Loops

The left ventricular cycle features six phases:

Isovolumetric Contraction: QRS depolarisation triggers contraction; LV pressure exceeds left atrial pressure, closing the mitral valve ( S1 ). All valves remain closed while intraventricular pressure spikes.

Rapid Ejection: LV pressure exceeds aortic diastolic pressure (~80 mmHg); aortic valve opens, rapidly discharging stroke volume.

Reduced Ejection: Ventricular repolarisation begins (T wave); outflow velocity slows.

Isovolumetric Relaxation: LV pressure falls below aortic pressure, closing the aortic valve ( S2 ; physiological splitting widens on inspiration due to delayed P2 from augmented venous return).

Rapid Filling: LV pressure drops below left atrial pressure, opening the mitral valve. Rapid filling generates an S3 in volume overload or dilated cardiomyopathy.

Diastasis & Atrial Systole: Atrial contraction adds 15–20% of EDV ("atrial kick"). Contracting into a stiff ventricle generates a pathological S4 .

The PV loop defines stroke volume (SV = EDV - ESV) and ejection fraction (EF = SV / EDV):

Increased Preload: Shifts EDV rightward along the diastolic curve, increasing SV via Frank-Starling mechanics.

Increased Afterload: Raises peak systolic pressure, increases ESV, and decreases SV.

Increased Inotropy: Shifts the end-systolic curve (ESPVR) leftward, increasing SV and reducing ESV.

Systemic Vascular Resistance & Coronary Perfusion

SVR = [(MAP - CVP) / CO] × 80. By Poiseuille's law (R ∝ 1/r⁴), arteriolar radius is the chief vascular resistance regulator.

The left ventricular subendocardium is perfused almost exclusively in diastole: CPP = Aortic Diastolic Pressure − LVEDP \text{CPP} = \text{Aortic Diastolic Pressure} - \text{LVEDP} CPP = Aortic Diastolic Pressure − LVEDP

Tachycardia shortens diastole disproportionately. Aortic regurgitation reduces aortic diastolic pressure, while aortic stenosis elevates LVEDP; both severely reduce CPP, precipitating subendocardial ischaemia.

Autonomic Reflex Arcs

Baroreceptors: Carotid sinus (CN IX) and aortic arch (CN X) mechanoreceptors project to the medullary nucleus tractus solitarius (NTS). Elevated pressure increases firing, stimulating vagal parasympathetic nuclei (bradycardia) and inhibiting sympathetic outflow (vasodilatation).

Chemoreceptors: Peripheral bodies (carotid CN IX, aortic CN X) detect hypoxaemia (PaO₂ < 8.0 kPa), hypercapnia, and acidosis. Central chemoreceptors in the ventrolateral medulla sense [H⁺] in CSF generated by diffusing arterial CO₂.

  • 2. Respiratory Gas Exchange & Mechanics
  • Lung Volumes, Capacities & Dead Space

Volumes: Tidal Volume (TV ~500 mL), Inspiratory Reserve Volume (IRV ~3,000 mL), Expiratory Reserve Volume (ERV ~1,100 mL), Residual Volume (RV ~1,200 mL). RV cannot be measured by spirometry; it requires helium dilution or plethysmography.

Functional Residual Capacity (FRC = ERV + RV): Resting volume where inward lung recoil balances outward chest wall recoil.

Physiological Dead Space (VD): Calculated via the Bohr-Enghoff equation : VD / VT = ( PaCO 2 − PECO 2 ) / PaCO 2 \text{VD} / \text{VT} = (\text{PaCO}_2 - \text{PECO}_2) / \text{PaCO}_2 VD / VT = ( PaCO 2 ​ − PECO 2 ​ ) / PaCO 2 ​ Normal ratio is 0.20–0.35; it increases in pulmonary embolism and emphysema.

Alveolar Gas Equation & A-a Gradient

Expected alveolar oxygen tension: PAO 2 = FiO 2 × ( Patm − PH 2 O ) − ( PaCO 2 / R ) \text{PAO}_2 = \text{FiO}_2 \times (\text{Patm} - \text{PH}_2\text{O}) - (\text{PaCO}_2 / \text{R}) PAO 2 ​ = FiO 2 ​ × ( Patm − PH 2 ​ O ) − ( PaCO 2 ​ / R )

On room air at sea level: PAO₂ ≈ 20.0 kPa - (PaCO₂ / 0.8).

A-a Gradient (PAO₂ - PaO₂): Normal is < 2.0 kPa (or Age/4 + 4 mmHg).

Normal A-a with Hypoxaemia: Indicates alveolar hypoventilation (sedatives, neuromuscular disease) or high altitude.

Elevated A-a with Hypoxaemia: Indicates V/Q mismatch, shunt, or diffusion barrier defect.

V/Q Mismatch vs. True Shunt

V/Q Mismatch (COPD, asthma): Low V/Q units readily respond to modest supplemental oxygen.

True Shunt (V/Q = 0; ARDS, consolidation, right-to-left shunts): Blood bypasses ventilated alveoli. Hallmark: Hypoxaemia fails to correct with 100% supplemental oxygen.

Oxygen-Haemoglobin Dissociation Curve

Normal P50 is 3.5 kPa (26.6 mmHg) .

Right Shift (decreased affinity, O2 release): Acidosis (Bohr effect), hypercapnia, hyperthermia, elevated 2,3-DPG.

Left Shift (increased affinity, O2 holding): Alkalosis, hypocapnia, hypothermia, low 2,3-DPG, HbF, carboxyhaemoglobin.

MRCP Exam Pearl: Oxygen-Induced Hypercapnia in COPD: High-flow oxygen worsens acidosis primarily by reversing hypoxic pulmonary vasoconstriction (redirecting blood to unventilated alveoli, increasing dead space) and via the Haldane effect (oxygenating Hb displaces CO₂ into plasma). Target SpO₂ is 88–92%.

3. Renal Microcirculation & Neurohumoral Regulation

Glomerular Filtration Dynamics GFR = K f × [ ( P G C − P B S ) − ( π G C − π B S ) ] \text{GFR} = K_f \times [(P_{GC} - P_{BS}) - (\pi_{GC} - \pi_{BS})] GFR = K f ​ × [( P GC ​ − P BS ​ ) − ( π GC ​ − π BS ​ )]

Autoregulation (MAP 80–180 mmHg) relies on myogenic responses and tubuloglomerular feedback (macula densa detects luminal NaCl, releasing adenosine to constrict afferent arterioles).

Prostaglandins: Dilate afferent arterioles. NSAIDs block this, causing afferent constriction and acute GFR drops.

Angiotensin II: Constricts efferent arterioles to preserve P_GC. ACE inhibitors dilate efferent arterioles, reducing GFR during hypoperfusion.

Countercurrent Multiplication & Urea Recycling

The loop of Henle establishes a hypertonic medullary gradient (300 to 1,200 mOsm/kg):

Thin Descending Limb: Permeable to water via aquaporin-1 (AQP1); impermeable to solutes.

Thick Ascending Limb (TAL): Impermeable to water; actively transports Na⁺, K⁺, and 2Cl⁻ via apical NKCC2 cotransporters (inhibited by furosemide), creating a 200 mOsm/kg single effect.

Urea Recycling: ADH stimulates UT-A1/A3 transporters in medullary collecting ducts, recycling urea to generate ~50% of papillary hypertonicity. Vasa recta hairpin loops act as countercurrent exchangers to prevent solute washout.

Endocrine Fluid Homeostasis

RAAS: Juxtaglomerular renin cleaves angiotensinogen → Ang I → Ang II (via ACE). Ang II stimulates adrenal aldosterone, which binds mineralocorticoid receptors in principal cells to upregulate apical ENaC channels and basolateral Na⁺/K⁺-ATPase (sodium/water retention, potassium/hydrogen excretion).

Vasopressin (ADH): Released from posterior pituitary upon hyperosmolality (> 280 mOsm/kg) or hypovolaemia. Binds basolateral V2 receptors (Gs-coupled), activating cAMP/PKA to insert Aquaporin-2 (AQP2) water channels into apical membranes.

ANP: Released by stretched atria. Activates guanylyl cyclase (↑ cGMP), dilating afferent and constricting efferent arterioles to raise GFR, while inhibiting renin, aldosterone, and tubular sodium reabsorption.